Melanoma (Skin)Phase 2NCT00002860
SWOG-9430: Surgery in Treating Patients With Metastatic Melanoma
A Phase 2 study testing Surgery in people with Melanoma (Skin), run by SWOG Cancer Research Network at 124 sites in United States.
Trial summary
RATIONALE: Surgery may be effective therapy in treating patients with metastatic melanoma. PURPOSE: This phase II trial is studying how well surgery works in treating patients with metastatic melanoma. Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Melanoma (Skin)
- What is being tested?
- Surgery
- Type of treatment
- Surgery or procedure
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 77 participants
- Where
- 124 sitesUnited States
- Study dates
- Nov 1996to Dec 2010
- Phase
- Phase 2
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
DISEASE CHARACTERISTICS:
- Histologically confirmed metastatic melanoma that is deemed grossly surgically resectable
- Multiple resected sites or metastatic melanoma of unknown primary allowed provided all known disease can be grossly resected
- Recurrence in iliac lymph nodes after inguinal lymph dissection allowed
- No metastatic disease beyond the lesions planned for resection
- Confirmed by CT scan of chest, abdomen, pelvis, and CT or MRI of brain within 42 days of study
- Concurrent registration on protocol SWOG-9431 required
PATIENT CHARACTERISTICS:
Age:
- 18 and over
Performance status:
- SWOG 0-2
Hematopoietic:
- Not specified
Hepatic:
- Not specified
Renal:
- Not specified
Other:
- No other malignancy within the past 5 years except adequately treated basal cell or squamous cell skin cancer, carcinoma in situ of the cervix, or adequately treated stage I or II cancer from which patient is currently disease free
- Not pregnant
PRIOR CONCURRENT THERAPY:
Biologic therapy:
- Prior immunotherapy in the adjuvant or metastatic setting allowed
Chemotherapy:
- Prior chemotherapy in the adjuvant or metastatic setting allowed
Endocrine therapy:
- Prior hormonal therapy in the adjuvant or metastatic setting allowed
Radiotherapy:
- Prior radiotherapy in the adjuvant or metastatic setting allowed
Surgery:
- See Disease Characteristics
- At least 14 days since prior surgery in the adjuvant or metastatic setting
Other:
- Recovered from prior therapy
Trial locations and contacts
124 sites in 1 country.
124 sites in 1 country
United States124 sites
Saint Anthony's Hospital at Saint Anthony's Health Center
Alton, Illinois, 62002
Harrington Cancer Center
Amarillo, Texas, 79106
American Fork Hospital
American Fork, Utah, 84003
Alaska Regional Hospital Cancer Center
Anchorage, Alaska, 99508
University of Michigan Comprehensive Cancer Center
Ann Arbor, Michigan, 48109
Battle Creek Health System Cancer Care Center
Battle Creek, Michigan, 49017
St. Joseph Hospital Community Cancer Center
Bellingham, Washington, 98225
St. Luke's Hospital Cancer Center
Bethlehem, Pennsylvania, 18015
Mecosta County General Hospital
Big Rapids, Michigan, 49307
CCOP - Montana Cancer Consortium
Billings, Montana, 59101
Deaconess Billings Clinic - Downtown
Billings, Montana, 59101
Hematology-Oncology Centers of the Northern Rockies - Billings
Billings, Montana, 59101
Northern Rockies Radiation Oncology Center
Billings, Montana, 59101
St. Vincent Healthcare
Billings, Montana, 59101
Deaconess Billings Clinic Cancer Center
Billings, Montana, 59107
Beth Israel Deaconess Medical Center
Boston, Massachusetts, 02215
Bozeman Deaconess Hospital
Bozeman, Montana, 59715
Internal Medicine Associates of Bozeman
Bozeman, Montana, 59715
Olympic Hematology and Oncology
Bremerton, Washington, 98310
St. James Community Hospital
Butte, Montana, 59701
Aultman Hospital Cancer Center at Aultman Health Foundation
Canton, Ohio, 44710
St. Francis Medical Center
Cape Girardeau, Missouri, 63701
Cancer Center of Kansas - Chanute
Chanute, Kansas, 66720
Adena Regional Medical Center
Chillicothe, Ohio, 54601
Charles M. Barrett Cancer Center at University Hospital
Cincinnati, Ohio, 45267
MetroHealth's Cancer Care Center at MetroHealth Medical Center
Cleveland, Ohio, 44109
Riverside Methodist Hospital Cancer Care
Columbus, Ohio, 43214
CCOP - Columbus
Columbus, Ohio, 43215
Grant Riverside Cancer Services
Columbus, Ohio, 43215
Mount Carmel West Hospital
Columbus, Ohio, 43222
Doctors Hospital at Ohio Health
Columbus, Ohio, 43228
Grady Memorial Hospital
Delaware, Ohio, 43015
Barbara Ann Karmanos Cancer Institute
Detroit, Michigan, 48202
Cancer Center of Kansas - Dodge City
Dodge City, Kansas, 67801
Cancer Center of Kansas, P.A. - El Dorado
El Dorado, Kansas, 67042
Southeast Missouri Regional Cancer Center at Southeast Missouri Hospital
Gape Girardeau, Missouri, 63701
Wayne Memorial Hospital, Incorporated
Goldsboro, North Carolina, 27534
CCOP - Grand Rapids
Grand Rapids, Michigan, 49503
Lacks Cancer Center at Saint Mary's Mercy Medical Center
Grand Rapids, Michigan, 49503
Spectrum Health Cancer Care - Butterworth Campus
Grand Rapids, Michigan, 49503
Metropolitan Hospital
Grand Rapids, Michigan, 49506
Big Sky Oncology
Great Falls, Montana, 59405
Great Falls Clinic
Great Falls, Montana, 59405
Sletten Regional Cancer Institute
Great Falls, Montana, 59405
North Colorado Medical Center
Greeley, Colorado, 80631
Hackensack University Medical Center
Hackensack, New Jersey, 07601
St. Peter's Hospital
Helena, Montana, 59601
Holland Community Hospital
Holland, Michigan, 49423
University of Mississippi Medical Center
Jackson, Mississippi, 39216
Baptist Cancer Institute - Jacksonville
Jacksonville, Florida, 32207
Bronson Methodist Hospital
Kalamazoo, Michigan, 49007
West Michigan Cancer Center
Kalamazoo, Michigan, 49007
Borgess Medical Center
Kalamazooaa, Michigan, 49001
Glacier Oncology, PLLC
Kalispell, Montana, 59901
Kalispell Medical Oncology
Kalispell, Montana, 59901
Kalispell Regional Medical Center
Kalispell, Montana, 59901
Veterans Affairs Medical Center - Kansas City
Kansas City, Kansas, 64128
CCOP - Kansas City
Kansas City, Missouri, 64131
Cancer Center of Kansas - Kingman
Kingman, Kansas, 67068
Gundersen Lutheran Cancer Center at Gundersen Lutheran Medical Center
La Crosse, Wisconsin, 54601
Fairfield Medical Center
Lancaster, Ohio, 43130
Southwest Medical Center
Liberal, Kansas, 67901
St. Rita's Medical Center
Lima, Ohio, 45801
Logan Regional Hospital
Logan, Utah, 84321
McKee Medical Center
Loveland, Colorado, 80539
Strecker Cancer Center at Marietta Memorial Hospital
Marietta, Ohio, 45750
Fox Chase Virtua Health Cancer Program - Marlton
Marlton, New Jersey, 08053
Eastern Montana Cancer Center
Miles City, Montana, 59301
Community Medical Center
Missoula, Montana, 59801
Montana Cancer Center at St. Patrick Hospital and Health Sciences Center
Missoula, Montana, 59802
Montana Cancer Specialists at Montana Cancer Center
Missoula, Montana, 59802
Good Samaritan Regional Health Center
Mount Vernon, Illinois, 62864
Skagit Valley Hospital Cancer Care Center
Mount Vernon, Washington, 98273
Cottonwood Hospital Medical Center
Murray, Utah, 84107
Hackley Hospital
Muskegon, Michigan, 49443
Licking Memorial Cancer Care Program at Licking Memorial Hospital
Newark, Ohio, 43055
Cancer Center of Kansas - Newton
Newton, Kansas, 67114
McKay-Dee Hospital Center
Ogden, Utah, 84403
Cancer Center of Kansas, P.A. - Parsons
Parsons, Kansas, 67357
Northern Michigan Hospital
Petoskey, Michigan, 49770
Banner Good Samaritan Medical Center
Phoenix, Arizona, 85006
CCOP - Western Regional, Arizona
Phoenix, Arizona, 85006
Banner Thunderbird Medical Center
Phoenix, Arizona, 85306
Cancer Institute at Oregon Health and Science University
Portland, Oregon, 97239
Pratt Cancer Center of Kansas
Pratt, Kansas, 67124
Utah Valley Regional Medical Center - Provo
Provo, Utah, 84603
William Beaumont Hospital - Royal Oak Campus
Royal Oak, Michigan, 48073
Cancer Center of Kansas - Salina
Salina, Kansas, 67042
Utah Cancer Specialists at UCS Cancer Center
Salt Lake City, Utah, 84106
LDS Hospital
Salt Lake City, Utah, 84143
Fred Hutchinson Cancer Research Center
Seattle, Washington, 98104
Group Health Central Hospital
Seattle, Washington, 98104
Harborview Medical Center
Seattle, Washington, 98104
Swedish Cancer Institute at Swedish Medical Center - First Hill Campus
Seattle, Washington, 98114
University Cancer Center at University of Washington Medical Center
Seattle, Washington, 98195
North Puget Oncology at United General Hospital
Sedro-Woolley, Washington, 98284
Welch Cancer Center
Sheridan, Wyoming, 82801
Siouxland Regional Cancer Center
Sioux City, Iowa, 51101-1733
Siouxland Hematology-Oncology Associates
Sioux City, Iowa, 51101
Mercy Medical Center - Sioux City
Sioux City, Iowa, 51104
St. Luke's Regional Medical Center
Sioux City, Iowa, 51104
Sioux Valley Hospital and University of South Dakota Medical Center
Sioux Falls, South Dakota, 57104
Avera McKennan Hospital and University Health Center
Sioux Falls, South Dakota, 57105
Medical X-Ray Center
Sioux Falls, South Dakota, 57105
Cancer Care Northwest - Spokane South
Spokane, Washington, 99202
Mercy Medical Center Oncology Unit
Springfield, Ohio, 45504
Community Hospital of Springfield and Clark County
Springfield, Ohio, 45505
CCOP - St. Louis-Cape Girardeau
St Louis, Missouri, 63141
David C. Pratt Cancer Center at St. John's Mercy
St Louis, Missouri, 63141
Dixie Regional Medical Center
St. George, Utah, 84770
Munson Medical Center
Traverse City, Michigan, 49684
Arizona Cancer Center at University of Arizona Health Sciences Center
Tucson, Arizona, 85724
Cancer Center of Kansas - Wellington
Wellington, Kansas, 67152
Central Washington Hospital
Wenatchee, Washington, 98801
Wenatchee Valley Clinic
Wenatchee, Washington, 98801
Mount Carmel Cancer Services at Mount Carmel St. Ann's Hospital
Westerville, Ohio, 43081
Associates in Womens Health
Wichita, Kansas, 67203
Cancer Center of Kansas, P.A.
Wichita, Kansas, 67208
Cancer Center of Kansas, P.A. - Wichita
Wichita, Kansas, 67214
CCOP - Wichita
Wichita, Kansas, 67214
Via Christi Cancer Center at Via Christi Regional Medical Center
Wichita, Kansas, 67214
Wesley Medical Center
Wichita, Kansas, 67214
Cancer Center of Kansas - Winfield
Winfield, Kansas, 67156
Genesis - Good Samaritan Hospital
Zanesville, Ohio, 43701
About this study
Official title: A Phase II Trial of Complete Surgical Resection For Stage IV Melanoma -- Surgical Resection With Biological Evaluation and Clinical Follow-Up
RATIONALE: Surgery may be effective therapy in treating patients with metastatic melanoma.
PURPOSE: This phase II trial is studying how well surgery works in treating patients with metastatic melanoma.
Read the detailed description
OBJECTIVES:
- Assess overall and progression-free survival in patients with metastatic melanoma (beyond the draining lymph nodes) after complete surgical resection of all known disease.
- Determine the ability of the Southwest Oncology Group Melanoma Committee to enroll patients with metastatic melanoma who can be resected to a disease-free state.
OUTLINE: This is a multicenter study.
All patients undergo gross total resection of all known disease. Patients whose disease cannot be completely resected or who have disease recurrence after surgery are removed from study. Patients found to have microscopic residual disease after surgery are considered completely resected. Resected tissue is submitted for analysis on protocol SWOG-9431.
Patients may receive any adjuvant therapy (e.g., radiotherapy, interferon, and/or vaccines) deemed clinically appropriate by the treating physician.
Patients are followed periodically for 5 years after study entry.
PROJECTED ACCRUAL: A total of 100 eligible patients with completely surgically resected disease will be accrued for this study.
- Conditions
- Melanoma (Skin)
- Being tested
- Surgery
- Keywords
- stage IV melanoma, recurrent melanoma
- Medical subject headings
- Melanoma
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
SurgeryProcedure or surgery
Complete surgical resection of metastatic melanoma
| Study group | Role | What they receive |
|---|---|---|
| surgery | Other | Not described Receives: Procedure: Surgery |
What is being measured
The primary outcome is the main question the study is designed to answer.
Overall survival
Measured: 1-year
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted27 Jan 2003 (estimated)
- Study startNov 1996
- Primary completionDec 2006
- Study completionDec 2010
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (1)Papers the sponsor has linked to this study.
- Other trials for Melanoma (Skin)Studies of the same condition, open and under way.
- More trials run by SWOG Cancer Research NetworkThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase 2
- Primary purpose
- Treatment
- Allocation
- Not applicable
- Intervention model
- Single group
- Masking
- None (open label)
- Enrolment
- 77 participants (actual)
Sponsor and investigators
- Lead sponsor
- SWOG Cancer Research Network
- Sponsor type
- Research network
- Collaborators
- National Cancer Institute (NCI), Eastern Cooperative Oncology Group
- Responsible party
- Sponsor
- Investigators
- Jeffrey A. Sosman, MD, Study chair, Vanderbilt-Ingram Cancer CenterJohn M. Kirkwood, MD, Study chair, University of Pittsburgh
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT00002860
- Sponsor's protocol ID
- CDR0000065130
- Other IDs
- U10CA032102, SWOG-9430, ECOG-S9430
- Status last verified
- Jan 2012
- First submitted
- 1 Nov 1999
- Last updated
- 13 Jan 2012
- Results posted
- No
- Data monitoring committee
- No
Publications
Sondak VK, Liu PY, Warneke J, et al.: Surgical resection for stage IV melanoma: a Southwest Oncology Group trial (S9430). [Abstract] J Clin Oncol 24 (Suppl 18): A-8019, 457s, 2006.
Study at a glance
From the registry record, last updated by the sponsor on 13 Jan 2012. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- A Phase II Trial of Complete Surgical Resection For Stage IV Melanoma -- Surgical Resection With Biological Evaluation and Clinical Follow-Up
- ClinicalTrials.gov ID
- NCT00002860
- Acronym / sponsor ID
- CDR0000065130
- Conditions
- Melanoma (Skin)
- Keywords
- stage IV melanoma, recurrent melanoma
- Phase
- Phase 2
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 77 participants (actual)
- Lead sponsor
- SWOG Cancer Research NetworkResearch network
- Collaborators
- National Cancer Institute (NCI), Eastern Cooperative Oncology Group
- Study start
- Nov 1996
- Primary completion
- Dec 2006 (actual)
- Study completion
- Dec 2010 (actual)
- First posted
- 27 Jan 2003 (estimated)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
RATIONALE: Surgery may be effective therapy in treating patients with metastatic melanoma.
PURPOSE: This phase II trial is studying how well surgery works in treating patients with metastatic melanoma.
Detailed description
OBJECTIVES:
- Assess overall and progression-free survival in patients with metastatic melanoma (beyond the draining lymph nodes) after complete surgical resection of all known disease.
- Determine the ability of the Southwest Oncology Group Melanoma Committee to enroll patients with metastatic melanoma who can be resected to a disease-free state.
OUTLINE: This is a multicenter study.
All patients undergo gross total resection of all known disease. Patients whose disease cannot be completely resected or who have disease recurrence after surgery are removed from study. Patients found to have microscopic residual disease after surgery are considered completely resected. Resected tissue is submitted for analysis on protocol SWOG-9431.
Patients may receive any adjuvant therapy (e.g., radiotherapy, interferon, and/or vaccines) deemed clinically appropriate by the treating physician.
Patients are followed periodically for 5 years after study entry.
PROJECTED ACCRUAL: A total of 100 eligible patients with completely surgically resected disease will be accrued for this study.
Study design
- Primary purpose
- Treatment
- Allocation
- Not applicable
- Intervention model
- Single group
- Masking
- None (open label)
- Number of arms
- 1
| Arm | Type | Receives |
|---|---|---|
| surgery | Other | Procedure: Surgery |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| SurgeryComplete surgical resection of metastatic melanoma | Procedure or surgery | surgery |
Primary outcome
Overall survival
Time frame: 1-year
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 13 Jan 2012.
- Results publicationSondak VK, Liu PY, Warneke J, et al.: Surgical resection for stage IV melanoma: a Southwest Oncology Group trial (S9430). [Abstract] J Clin Oncol 24 (Suppl 18): A-8019, 457s, 2006.
Related trials for Melanoma (Skin)
RecruitingPhase 1/2
Study of INBRX-106 and INBRX-106 in Combination With Pembrolizumab (Keytruda®) in Subjects With Locally Advanced or Metastatic Solid Tumors (Hexavalent OX40 Agonist)
Solid Tumor, Non-Small Cell Lung Cancer
RecruitingPhase 1
IL-17 Blockade to Decrease irAEs (REPLAY)
Metastatic Melanoma
Enrolling by invitationObservational study
Natural History Study of Early Life Exposures in Agriculture (ELEA)
Prostate Cancer, Leukemia
RecruitingPhase 1
A Feasibility Study Utilizing Immune Recall to Increase Response to Checkpoint Therapy
Melanoma
Active, not recruitingPhase 1/2
A Study of Dapansutrile Plus Pembrolizumab in Patients With PD-1 Refractory Advanced Melanoma
Melanoma
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Jeffrey A. Sosman, MD study chair
Vanderbilt-Ingram Cancer Center
John M. Kirkwood, MD study chair
University of Pittsburgh
124 sites in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A Phase 2 study testing Surgery in people with Melanoma (Skin), run by SWOG Cancer Research Network at 124 sites in United States.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 13 Jan 2012. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 124 sites in United States. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
What does this phase mean?
Phase 2 studies give the treatment to a larger group to see whether it has the intended effect and to keep checking safety.
Not every study follows the same path, and some studies (observational studies, device studies) have no phase.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Overall survival (time frame: 1-year). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT00002860, which also lists 1 linked publication.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 13 Jan 2012.